BioSymetrics
BioSymetrics is a phenomics-driven AI drug discovery company that combines proprietary machine learning, the Phenograph knowledge graph, and zebrafish in vivo validation to identify higher-confidence therapeutic targets for pharmaceutical, biotech, and U.S. defense partners.
- Company typePrivate
- Founded2016
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What BioSymetrics does
BioSymetrics is a phenomics-driven AI drug discovery company that builds target identification and precision-medicine programs by connecting human disease phenotype and genotype data to in vivo validation. Its core platform, Elion, combines machine-learning predictions with high-content zebrafish phenotypic screening in 96-well plates, supported by the patent-pending Contingent AI™ framework for denoising and integrating clinical data and the Phenograph knowledge graph that maps phenotypes to genes to diseases to drugs across model systems. The platform is reported to leverage more than 77 million longitudinal patient records and over 1 million genomic profiles, with the KCC2 Epilepsy program generating over 12,000 zebrafish videos analyzed via proprietary computer vision at 15,000+ data points each.
The company operates as a B2B enterprise platform with no consumer distribution, monetizing through co-development agreements, licensing and royalty structures, and select non-dilutive grants. Commercial customers and partners include Pfizer, Deerfield Management (under a five-year joint venture), Sema4 (up to 10 therapeutic programs), Janssen Pharmaceuticals, BrainStorm Therapeutics, Northwell Health, and Brigham and Women's Hospital. Recent expansion into U.S. defense applications is anchored by the Pathfinder Consortium, targeting the $400M–$1.2B per-program federal countermeasure procurement market. Following the April 2025 close of its merger with Renovaro, BioSymetrics operates as a wholly owned subsidiary of Lunai Bioworks (NASDAQ: LNAI), with a remote-first workforce of 11–50 employees concentrated in the New York/Boston and Toronto areas.
BioSymetrics firmographics
Firmographics- Name
- BioSymetrics
- Legal name
- BioSymetrics Inc.
- Website
- https://biosymetrics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioSymetrics is a phenomics-driven AI drug discovery company that combines proprietary machine learning, the Phenograph knowledge graph, and zebrafish in vivo validation to identify higher-confidence therapeutic targets for pharmaceutical, biotech, and U.S. defense partners.
- Ownership category
- akta.pro rank
BioSymetrics industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)
Keywords
Where BioSymetrics is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
BioSymetrics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Defense Collaboration Revenue: Revenue-generating defense-focused collaboration through BioSymetrics for AI-enabled chemical threat assessment with government/biotech partners. Initial engagement underway with additional discussions ongoing.
- Pharmaceutical Partnership Agreements: Co-development and pharmaceutical partnering structures for development-ready neurology programs. Includes licensing agreements and downstream co-development structures with pharmaceutical companies.
- NIH Grant Funding: $1.85 million NIH STTR grant awarded to BioSymetrics and Brigham and Women's Hospital for AI-powered alcohol use disorder therapeutic discovery platform.
- Rare Disease Data Collaboration: Revenue-generating partnerships with pharmaceutical companies enabled by patient cohort development for rare neurological disorders through Geneial collaboration.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
BioSymetrics product offering
Product offeringCore offering
BioSymetrics operates the Elion phenomics-driven drug discovery and development platform that connects disease phenotype and genotype data between humans and model systems, using machine learning to predict novel gene targets and coupling predictions with high-content in vivo validation using zebrafish phenotypic models. The platform integrates clinical data, genomic profiles, and experimental readouts through the patented Contingent AI™ framework and the Phenograph knowledge graph, targeting pharmaceutical partners in neurological, cardiometabolic, and rare disease programs.
Product overview
BioSymetrics is a phenomics-driven AI drug discovery company offering a unified platform centered on the Elion platform, which integrates machine learning predictions with in vivo validation. The core technology stack includes Contingent AI™ (their patented AI iteration framework for denoising and integrating clinical data), the Phenograph (a knowledge linkage map connecting phenotypes to genes to drugs), and a Zebrafish Phenotypic Validation Platform for in vivo target validation. These components work together to connect disease phenotype and genotype data between humans and model systems, enabling higher-confidence target discovery and precision medicine development faster than traditional reductionist approaches.
Differentiator
Problem solved
Functional benefit
Brands
- Elion: The phenomics-driven drug discovery and development platform that uses machine learning predictions and in vivo validation with zebrafish models.
- Contingent AI
Products and services
- Elion Platform The phenomics-driven drug discovery and development platform that connects disease phenotype and genotype data between humans and model systems, uses machine learning to make predictions, and couples with high-content in vivo validation using zebrafish models. For pharmaceutical and biotech partners seeking AI-powered target discovery.
- Zebrafish Phenotypic Validation Platform In vivo validation platform using zebrafish phenotypic models with scalable experimentation in 96-well plates and computer vision analysis, enabling high-content phenotypic readouts within days of gene manipulation. For pharmaceutical researchers seeking rapid in vivo validation of AI-predicted targets.
Quantifiable outcome
- Twice the likelihood of clinical success for targets grounded in human genetic evidence
- +1 more outcomes
Companies that use BioSymetrics
Customer profileNamed customers8 records
Segments4 records
Ideal customer profiles3 records
BioSymetrics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability10 records
Feature5 records
BioSymetrics partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- BrainStorm TherapeuticscoreStrategic collaboration to jointly discover and advance novel therapeutic targets for neurological diseases, beginning with rare genetic epilepsies and Parkinson's disease. Supported by LouLou Foundation grant. Combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation with BrainStorm's proprietary human-derived organoid systems.
- GeneialminorNon-binding Letter of Intent for strategic collaboration focused on converting patient-generated data into trial-ready cohorts for rare neurological disorders. Aims to integrate datasets across multiple patient registries for pharmaceutical partnerships.
- Pathfinder ConsortiumcoreNational academic-industry alliance through BioSymetrics designed to consolidate U.S. chemical warfare preparedness resources into unified infrastructure for accelerated medical countermeasure development. Includes Harvard, Brigham and Women's Hospital, University of Utah, Purdue, and University of Colorado. Targets $400M-$1.2B federal procurement market per program with 3-year development timeline.
- Leiden University Medical CenterminorMulti-institutional research collaboration leading to identification of serum protein biomarkers predictive of disease progression in Duchenne Muscular Dystrophy. Validated RGMA, ART3, and ANTXR2 as disease progression indicators.
- Brigham and Women's HospitalminorNIH STTR grant collaboration ($1.85M) to develop AI-powered platform for alcohol use disorder therapeutic discovery. Uses AI and zebrafish screening to accelerate AUD treatment development.
- Deerfield ManagementcoreFive-year joint venture to accelerate advancement of new therapeutics with initial focus on cardiovascular and neurological diseases. Combines BioSymetrics' AI-powered target discovery with Deerfield's drug discovery and commercial modeling capabilities.
- Sema4coreStrategic partnership leveraging Sema4's Centrellis health intelligence platform and BioSymetrics' Elion phenotypic drug discovery platform. Up to 10 therapeutic programs in cardiovascular, rare and neurological diseases. Initial focus on atherosclerosis.
- Janssen PharmaceuticalsminorCollaboration to predict onset and severity of COVID-19 using machine learning. Used Contingent-AI engine across several projects to characterize high-risk populations and identify markers for clinical phenotype.
- HumanigenminorPartnership supporting Humanigen's Phase 3 study of lenzilumab for COVID-19. Applied phenotypic-driven drug discovery to investigate patient subsets and identify CRP as biomarker for precision use of lenzilumab.
- Northwell HealthminorPartnership for ARDS research and COVID-19 phenogrouping studies. Co-authored research on COVID-19 ARDS patient mortality factors.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
BioSymetrics competitors and assessment
Company assessmentDirect peers
- Schrödinger: Computational chemistry and physics-based drug design platform serving pharma partners. Comparable in monetizing drug-discovery software capabilities through enterprise and partnership deals.
- XtalPi: AI + quantum physics drug discovery platform with major pharma partnerships. Comparable in serving pharma R&D with computational prediction engines and co-development deal structures.
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML to identify novel targets. Directly comparable in using phenotypic data and in vivo validation to complement in silico predictions, and a leader in the same category BioSymetrics competes in.
- Insitro: ML-driven drug discovery platform that integrates engineered in vitro disease models with patient genomics data. Closely comparable to BioSymetrics' combination of clinical-scale data integration and biological validation for target discovery.
- Atomwise: Pioneer in AI-driven small-molecule discovery using structure-based design and ML. BioSymetrics' Chief Strategy Officer previously worked at Atomwise, and both companies pursue pharma partnerships for AI-discovered therapeutics.
- Exscientia: End-to-end AI drug discovery company with clinical-stage assets and major pharma partnerships. Comparable in deploying AI to compress target-to-candidate timelines and in building pharma co-development deals.
Emerging players
- CytoReason: AI platform for immune-system disease modeling and drug discovery, focused on pharma data partnerships. Comparable in using patient-derived multi-omics data to support pharma target and biomarker decisions.
- Lantern Pharma: AI-driven oncology drug development company using machine learning to identify responder populations and repurpose therapeutics. Comparable in applying ML/AI to drug-discovery pipelines with pharma partnership economics.
- twoXAR Pharmaceuticals: AI-driven drug discovery company leveraging patient-derived data and ML to identify novel indications and drug candidates. Comparable in data-driven target prioritization and pharma partnering model.
Broad incumbents
- Ginkgo Bioworks: Large synthetic biology and cell-engineering platform that has built a partner network (in which BioSymetrics is an inaugural member). Adjacent rather than direct overlap, but both pursue data-rich, partner-driven biology discovery for pharma and government.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioSymetrics social profiles
Digital presenceBioSymetrics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioSymetrics leadership team
Management profileNumber of profiles
Profiles12 records
BioSymetrics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioSymetrics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioSymetrics
What does BioSymetrics do?
BioSymetrics operates the Elion phenomics-driven drug discovery and development platform that connects disease phenotype and genotype data between humans and model systems, using machine learning to predict novel gene targets and coupling predictions with high-content in vivo validation using zebrafish phenotypic models. The platform integrates clinical data, genomic profiles, and experimental readouts through the patented Contingent AI™ framework and the Phenograph knowledge graph, targeting pharmaceutical partners in neurological, cardiometabolic, and rare disease programs.
Is BioSymetrics a public or private company?
BioSymetrics is a private company. It is classified as corporate owned and is currently operating.
When was BioSymetrics founded?
BioSymetrics was founded in 2016. It employs 11 to 50 people.
Where is BioSymetrics based?
BioSymetrics is headquartered in New York, United States, in the North America region.
How does BioSymetrics make money?
Four revenue lines are on record. Defense Collaboration Revenue is the primary driver. The others are pharmaceutical Partnership Agreements, NIH Grant Funding and rare Disease Data Collaboration.
Who are BioSymetrics's main competitors?
Direct peers on record are Schrödinger, XtalPi, Recursion Pharmaceuticals, Insitro, Atomwise and Exscientia. Emerging players are CytoReason, Lantern Pharma and twoXAR Pharmaceuticals. Ginkgo Bioworks is listed as a broad incumbent.
Does BioSymetrics have an API?
No public API is recorded for BioSymetrics.
What industry is BioSymetrics in?
BioSymetrics's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.